Table 1.
Non-viral method | Model | Maximal efficiency | Cell survival | References | ||
---|---|---|---|---|---|---|
Precursors | Post-mitotic cells | DNA plasmids | RNAi | |||
Ca2+phosphate/DNA co-precipitation | erHCn | Typically between 1 and 5%; 12 and 27% under highly controlled conditions | Efficient %n.c. | %n.c. | Goetze et al., 2004 | |
Lipofection | nmCGn | Effective (≥50% Knock-down) | %n.c. | %n.c. | Butcher et al., 2009 | |
erHCn/erCn | 20–25% / 25–30%a | – | 100%b | Ohki et al., 2001; Dalby et al., 2004 | ||
erHCn | – | 73%c | 89–96% | Tonges et al., 2006 | ||
Biolistics | Typically around 2%, rarely reaches 10% in cultured neurons, up to 34% in slice culture | – | %n.c. | Karra and Dahm, 2010 | ||
nr/arDRGn/ SCGn | 5% | – | %n.c. | Dib-Hajj et al., 2009 | ||
Sonoporation | DRGn | 31% | 35% | Lin et al., 2010 | ||
Electroporation “Nucleofection” | nr/ar/amDRGn/SCGn | 5–20% | Efficient | %n.c. | Dib-Hajj et al., 2009 | |
ecDRGn | 37% | Martinez and Hollenbeck, 2003 | ||||
mNSC | 88% | Efficient >50% | 78% | Bertram et al., 2012d | ||
hNPCs | 10–20% | 44% | Dieterlen et al., 2009 | |||
arDRGn/erDRGn/ecDRGn/SCGn/ erHCn | 39–42% | %n.c. | Chadborn et al., 2006; Jones et al., 2006; MacGillavry et al., 2009; Ketschek and Gallo, 2010; McCall et al., 2012; Pristera et al., 2012; Kirton et al., 2013 |
erHCn, embryonic rat hippocampal neurons; hNPCs, human neural progenitor cells; NSC, neural stem cells; CGns, cerebellar granule neurons; SCGn, superior cervical ganglion neurons. amDRGn, adult Mouse DRGn; emDRGn, embryonic mouse DRGn; arDRGn, adult Rat DRGn; nrDRGn, neonatal rat DRGn; ecDRGn, embryonic chick DRGn; %n.c., percent not communicated.
Lipofectamine 2000™.
The authors state that 100% of the cells in transfected cultures are viable.
Stearyl-R8.
Nucleofector® 4D.